查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
连接酶市场 - 全球和区域分析：按产品、产地、应用、最终用户、国家 - 分析和预测（2025-2035 年）
市场调查报告书
商品编码
1711585

连接酶市场 - 全球和区域分析：按产品、产地、应用、最终用户、国家 - 分析和预测（2025-2035 年）

Ligase Market - A Global and Regional Analysis: Focus on Product, Source, Application, End User, and Country - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 110 Pages | 商品交期: 1-5个工作天内

价格

预测期内，即 2025-2035 年，全球连接酶市场规模预计将以 5.61% 的复合年增长率扩张。

预计全球连接酶市场的成长将受到以下因素的推动：全球感染疾病和遗传病的流行率不断上升、人们对基于酶的诊断测试的认识不断提高以及开展研发的资金充足。

全球连接酶市场正在快速发展，用于疾病检测的各种连接酶产品的研发活动显着增加，凸显了连接酶在医疗保健中的重要性。连接酶在分子诊断方法中起着关键作用，确保了标靶治疗药物的安全有效应用。全球连接酶市场上的大多数公司都提供连接试剂套件和含酶的产品。

增加基于酶的分子诊断的研发投资是连接酶市场的主要机会之一。多家诊断和製药公司正在合作进行药物开发，利用连接酶作为多种疾病的治疗工具，实现高效的诊断、治疗方法选择、剂量选择和治疗监测。

在连接酶的开发中已经采用了几种技术来检测和量化特定的 DNA 或 RNA 序列。此连接酶市场领域细分为连接酶炼式反应 (LCR)、连接酶检测反应 (LDR)、次世代定序(NGS)、重复扩增检测 (RED)、滚环扩增 (RCA)、邻位连接分析 (PLA)、分子克隆、连接介导的 PCR、突变检测和其他应用，如药物发现目标。

  • 连接酶炼式反应 (LCR)：LCR 是一种扩增过程，与聚合酵素链锁反应(PCR) 相反，它涉及使用耐热连接酶将两个探针或不同的粒子连接在一起，然后按照标准 PCR 循环进行扩增。
  • 连接酶检测反应（LDR）：LDR 是一种依靠连接酶炼式反应（LCR）将一对互补探针连接到目标 DNA 单链上的方法。此技术利用基于高保真度的耐热 DNA 连接酶，可以区分错配探针的连接。
  • 次世代定序(NGS)：次世代定序使用 DNA 连接酶来识别 DNA 序列中特定位置处核苷酸的存在或不存在。这种定序作用依赖 DNA 连接酶明确识别和连接碱基的能力。
  • 连接介导的 PCR：连接介导的 PCR 过程使得无需从大分子（例如扩增的酵母人工染色体 (YAC)）进行亚克隆即可产生原型定序模板。

按产品领域划分，T4 DNA 连接酶预计将占据主导地位。这是由于 T4 DNA 连接酶的使用日益增多，它是套件和酶供应商向最终用户提供的最常用的酶。

全球连接酶市场以大肠桿菌衍生产品为主。大肠桿菌连接酶是一种常用的连接酶，用于在将分子引入细胞之前连接其重组末端。从大肠桿菌中可以大量获得T4 RNA连接酶、T4 DNA连接酶、大肠桿菌DNA连接酶、盐T4 DNA连接酶等产品。

分子克隆过程在应用领域占据主导地位，而NGS则在全球连接酶市场中用于新兴诊断。随着各种克隆技术（属于分子克隆）的发展，这种程序的使用也越来越广泛，DNA片段重组的难度和速度也越来越快。

在全球连接酶市场中，研究机构和实验室占据最终用户领域，特别是因为有许多研究机构进行专注于确定连接酶的诊断应用的研究。

全球连接酶市场的最新趋势

  • 2022年1月，ArcticZymes Technologies推出了ArcticZymes R2DTM Ligase、IsoPol BST+High Concentration Glycerol FREE、M-SAN HQ ELISA Kit、M-SAN HQ等新产品。
  • 2022 年 4 月，Codexis, Inc. 和 Molecular Assemblies, Inc. 合作，为酵素工程和 DNA 酶促合成提供差异化、经济高效的解决方案。
  • 2022 年 5 月，QIAGEN 收购了 BLIRT eu 96% 的股份，BLIRT eu 是一家位于波兰格但斯克的生命科学产业重组酶製造商。此次收购旨在为酵素和试剂业务提供进一步的成长潜力。
  • 2021年7月，默克公司向位于达姆施塔特的全球总部投资2.825亿美元。默克公司正在为其医疗保健业务部门建立一个新的转化科学中心和一个新的学习中心。

产品/创新策略：本报告将连接酵素套件和酵素都视为基于产品的公司。这些公司正积极推行关键业务策略，将研发成功转化为商业性临床环境。

成长/行销策略：大规模平行定定序及其应用的爆炸性成长正在影响医疗保健的所有领域，特别是基于酵素的分子诊断。连接酶市场的主要组成部分包括各种基于连接酶的产品和连接试剂套件，通常由测试公司和测试服务机构自行购买。该报告提供了整个工作流程的详细说明，以及考虑用于检查的应用程式的定价分析。

竞争策略：分析并描述全球连结酶市场的主要企业概况。此外，它还对全球连字市场中的参与企业进行了详细的竞争基准化分析，以呈现清晰的市场格局，帮助读者了解参与企业之间的竞争情况。此外，伙伴关係、协议和联盟等全面的竞争策略可帮助读者了解市场中尚未开发的收益来源。

本报告概述了全球连接酶市场，包括按产品、产地、应用、最终用户和国家分類的趋势，以及参与市场的公司概况。

目录

执行摘要

第一章 市场概述

  • 概述
  • 主要趋势
  • 专利分析
  • 监管分析
  • 定价分析

第二章 市场动态

  • 概述
    • 影响分析
  • 市场驱动因素
  • 市场限制
  • 市场机会

第三章全球连结酶市场：竞争格局

  • 概述
  • 企业策略
  • 商务策略
  • 市场占有率分析

4. 全球连结酶市场（按产品类型划分）（百万美元），2023 年至 2035 年

  • 概述
  • 快速连接酶
  • T4 DNA连接酶
  • 大肠桿菌DNA连接酶
  • Tth DNA连接酶
  • T4 RNA连接酶
  • Pfu DNA连接酶
  • 其他的

5. 全球连结酶市场（按来源划分）（百万美元），2023 年至 2035 年

  • 概述
  • 古菌
  • 大肠桿菌
  • 嗜热菌
  • 激烈火球菌
  • 其他的

6. 全球连结酶市场（按应用划分）（百万美元），2023 年至 2035 年

  • 概述
  • 连接酶炼式反应（LCR）
  • 连接酶检测反应（LDR）
  • 次世代定序（NGS）
  • 重复增强检测（RED）
  • 滚圆放大器（RCA）
  • 邻位连接试验（PLA）
  • 分子克隆
  • 连接介导PCR
  • 突变检测
  • 其他的

7. 全球连结酶市场，按最终用户划分（百万美元），2023 年至 2035 年

  • 概述
  • 实验室和研究机构
  • 製药和生物製药公司
  • 诊断实验室
  • 其他的

8. 全球连结酶市场（按地区划分）（百万美元），2023 年至 2035 年

  • 概述
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 荷兰
    • 其他的
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 中东
    • 非洲

第九章 公司简介

  • Agilent Technologies, Inc.
  • ArcticZymes Technologies ASA
  • BD
  • Bio-Rad Laboratories, Inc.
  • Codexis, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Inspiralis Limited, Inc.
  • Merck KGaA
  • New England Biolabs（UK）Ltd.
  • Promega Corporation
  • QIAGEN NV
  • SBS Genetech
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.
  • Emerging Companies
Product Code: BHL1220SB

Global Ligase Market Industry Overview

The global ligase market is expected to grow at a CAGR of 5.61% during the forecast period from 2025 to 2035. The growth in the global ligase market is expected to be driven by factors such as the increasing prevalence of infectious and genetic diseases on a global level, rising awareness of enzyme based diagnostic testing and significant number of funding for executing research and development.

Market Lifecycle Stage

The global ligase market is progressing rapidly with a significant increase in the research and development activities pertaining to a wide range of ligase product for disease detection, accentuating their criticality in healthcare. Ligase enzyme has a critical role in the molecular diagnostics approach, as it ensures the safe and effective application of targeted therapeutics. Most of the players in the global ligase market offer products encompassing the ligation kits and enzymes.

Increasing investments in the R&D for enzyme-based molecular diagnostics is one of the major opportunities in the ligase market. Several diagnostics and pharmaceutical companies are working collaboratively on drug development and using ligase as a therapeutic means for applications in several disease indications in order to enable efficient diagnosis, treatment selection, dosage selection, and treatment monitoring.

Impact

Several techniques are employed in the development of ligase utilization to detect and quantify specific DNA or RNA sequences. This ligase market space has been segmented into applications that includes ligase chain reaction (LCR), ligase detection reaction (LDR), next-generation sequencing (NGS), repeat expansion detection (RED), rolling circle amplification (RCA), proximity ligation assay (PLA), molecular cloning, ligation mediated PCR, mutation detection, and other application such as drug target. Some of these technologies are described briefly as follows:

  • Ligase chain reaction (LCR): LCR is an amplification process that contrasts with polymerase chain reaction (PCR), which includes a thermostable ligase to join two probes or different particles together, which can then be amplified by standard PCR cycling.
  • Ligase detection reaction (LDR): LDR is a ligase chain reaction (LCR) dependent methodology which that involves a single pair of complementary probes to one strand of targeted DNA. This technique utilizes a high fidelity based thermostable DNA ligase that can distinguish against the ligation of mismatched probes.
  • Next-generation sequencing (NGS): In next-generation sequencing, DNA ligase is used to identify the presence of the nucleotide at a specific position in a DNA sequence. The role of this sequencing depends upon the ability of DNA ligase to identify and consolidate bases in an unmistakable way.
  • Ligation mediated PCR: The process of ligation mediated PCR allows to generate prototypical sequencing templates without subcloning from huge molecules, for example-., amplified yeast artificial chromosomes (YACs).

Market Segmentation:

Segmentation 1: by Product

  • Quick Ligase
  • T4 DNA ligase
  • E. coli DNA Ligase
  • Tth DNA Ligase
  • T4 RNA Ligase
  • Pfu DNA Ligase
  • Others

The global ligase market in the products segment is expected to be dominated by T4 DNA ligase. This is due to an increased usage of T4 DNA ligase, and it is the most commonly used ligase type among suppliers offering kits and enzymes to their end users.

Segmentation 2: by Source

  • Archaebacterium
  • Escherichia coli
  • Thermus thermophilus
  • Pyrococcus furiosus
  • Others

The global ligase market is dominated by the Escherichia coli source as it is a commonly used ligase to join recombinant ends of molecules before they are introduced into the cell. Products like T4 RNA ligase, T4 DNA ligase, E. coli DNA ligase, and salt T4 DNA ligase are obtained from Escherichia coli in abundance.

Segmentation 3: by Application

  • Ligase Chain Reaction (LCR)
  • Ligase Detection Reaction (LDR)
  • Next-Generation Sequencing (NGS)
  • Repeat Expansion Detection (RED)
  • Rolling Circle Amplification (RCA)
  • Proximity Ligation Assay (PLA)
  • Molecular Cloning
  • Ligation Mediated PCR
  • Mutation Detection
  • Others

The molecular cloning process dominates the application segment and NGS is the emerging diagnostic application in the global ligase market. The increase in the utilization of this procedure is due to various cloning techniques that have been created that fall under molecular cloning to improve the ease and speed at which DNA fragments can be recombined.

Segmentation 4: by End User

  • Research Laboratories and Institutions
  • Pharmaceutical and Biopharmaceutical Companies
  • Diagnostic Laboratories
  • Others

The research laboratories and institutions dominate the end-user segment in the global ligase market as research laboratories, particularly are most involved in carrying out the research studies that are focused on the identification of understanding the diagnostic application of ligase enzyme.

Recent Developments in Global Ligase Market

  • In January 2022, ArcticZymes Technologies launched new products such as ArcticZymes R2DTM Ligase, IsoPol BST+ High Concentration Glycerol FREE and M-SAN HQ ELISA Kit and M-SAN HQ
  • In April 2022, Codexis, Inc. and Molecular Assemblies, Inc., partnered to engineer enzymes and deliver differentiated and cost-effective solutions for the enzymatic synthesis of DNA.
  • In May 2022, QIAGEN acquired majority stake of 96% in BLIRT e.u.., a manufacturer of recombinant enzymes for the life science industry based in Gdansk, Poland. The acquisition was carried out to bring companies capabilities to create additional growth prospects to their enzymes and reagents business.
  • In July 2021, Merck invested $282.5 million at its global headquarters in Darmstadt. Company is involved in building a new translational science center for its healthcare business sector as well as a new learning center.

Demand - Drivers and Limitations

Following are the demand drivers for the global ligase market:

  • Growing need for Ligases in Disease Treatment
  • Rising Incidence of Diseases such as Cancer and Genetic Disorders
  • Rising Focus of Researchers on Non-Toxic Biocatalyst

The market is expected to face some limitations too due to the following challenges:

  • High Reception Costs Involving Small and Medium Enterprises
  • Variation in the Ability of Ligase to Repair

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The report considers ligase kits and enzymes both from the product-based companies. These companies are actively involved in undertaking significant business strategies to translate success in research and development into the commercial clinical setting.

Growth/Marketing Strategy: Owing to the explosion of massively parallel sequencing and its applications, all areas of healthcare have been affected, particularly enzyme-based molecular diagnostics. The key components in the ligase market consists of diverse range of ligase-based products and ligation kits, generally purchased by the testing companies and the testing services themselves. The entire workflow is well explained in the report along with pricing analysis considering the applications that are used in testing.

Competitive Strategy: Key players in the global ligase market analysed and profiled in the study, consisting of both products-based companies as well as few emerging companies. Moreover, a detailed competitive benchmarking of the players operating in the global ligase market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

The leading top segment players include ligase enzyme manufacturers that offers major products such as T4 DNA ligase, and E.coli DNA ligase, quick ligase, Pfu DNA ligase, T4 RNA ligase in the market.

Some of the prominent names established in this market are:

  • Agilent Technologies, Inc.
  • ArcticZymes Technologies ASA
  • BD
  • Bio-Rad Laboratories, Inc.
  • Codexis, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck KGaA
  • New England Biolabs (UK) Ltd.
  • Promega Corporation
  • QIAGEN N.V.
  • SBS Genetech
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

Research Methodology

1. Market Overview

  • 1.1 Overview
  • 1.2 Key Trends
  • 1.3 Patent Analysis
  • 1.4 Regulatory Analysis
  • 1.5 Pricing Analysis

2. Market Dynamics

  • 2.1 Overview
    • 2.1.1 Impact Analysis
  • 2.2 Market Drivers
  • 2.3 Market Restraints
  • 2.4 Market Opportunities

3. Global Ligase Market: Competitive Landscape

  • 3.1 Overview
  • 3.2 Corporate Strategies
    • 3.2.1 Mergers and Acquisitions
    • 3.2.2 Synergistic Activities
    • 3.2.3 Business Expansions and Funding
  • 3.3 Business Strategies
    • 3.3.1 Product Launches and Approvals
    • 3.3.2 Publications
    • 3.3.3 Licenses and Agreements
    • 3.3.4 Other Activities
  • 3.4 Market Share Analysis

4. Global Ligase Market (by Product Type), ($Million), 2023-2035

  • 4.1 Overview
  • 4.2 Quick Ligase
  • 4.3 T4 DNA Ligase
  • 4.4 E. coli DNA Ligase
  • 4.5 Tth DNA Ligase
  • 4.6 T4 RNA Ligase
  • 4.7 Pfu DNA Ligase
  • 4.8 Others

5. Global Ligase Market (by Source Type), ($Million), 2023-2035

  • 5.1 Overview
  • 5.2 Archaebacterium
  • 5.3 Escherichia coli
  • 5.4 Thermus thermophilus
  • 5.5 Pyrococcus furiosus
  • 5.6 Others

6. Global Ligase Market (by Application), ($Million), 2023-2035

  • 6.1 Overview
  • 6.2 Ligase Chain Reaction (LCR)
  • 6.3 Ligase Detection Reaction (LDR)
  • 6.4 Next-Generation Sequencing (NGS)
  • 6.5 Repeat Expansion Detection (RED)
  • 6.6 Rolling Circle Amplification (RCA)
  • 6.7 Proximity Ligation Assay (PLA)
  • 6.8 Molecular Cloning
  • 6.9 Ligation Mediated PCR
  • 6.10 Mutation Detection
  • 6.11 Others

7. Global Ligase Market (by End User), ($Million), 2023-2035

  • 7.1 Overview
  • 7.2 Research Laboratories and Institutions
  • 7.3 Pharmaceutical and Biopharmaceutical Companies
  • 7.4 Diagnostic Laboratories
  • 7.5 Other End Users

8. Global Ligase Market (by Region), ($Million), 2023-2035

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 France
    • 8.3.3 U.K
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Netherlands
    • 8.3.7 Rest-of-Europe
  • 8.4 Asia-Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest-of-Asia-Pacific (RoAPAC)
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Rest-of-Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 Middle East
    • 8.6.2 Africa

9. Company Profiles

  • 9.1 Agilent Technologies, Inc.
    • 9.1.1 Company Overview
    • 9.1.2 Product Portfolio
    • 9.1.3 Target Customers/End Users
    • 9.1.4 Analyst View
  • 9.2 ArcticZymes Technologies ASA
    • 9.2.1 Company Overview
    • 9.2.2 Product Portfolio
    • 9.2.3 Target Customers/End Users
    • 9.2.4 Analyst View
  • 9.3 BD
    • 9.3.1 Company Overview
    • 9.3.2 Product Portfolio
    • 9.3.3 Target Customers/End Users
    • 9.3.4 Analyst View
  • 9.4 Bio-Rad Laboratories, Inc.
    • 9.4.1 Company Overview
    • 9.4.2 Product Portfolio
    • 9.4.3 Target Customers/End Users
    • 9.4.4 Analyst View
  • 9.5 Codexis, Inc.
    • 9.5.1 Company Overview
    • 9.5.2 Product Portfolio
    • 9.5.3 Target Customers/End Users
    • 9.5.4 Analyst View
  • 9.6 F. Hoffmann-La Roche Ltd.
    • 9.6.1 Company Overview
    • 9.6.2 Product Portfolio
    • 9.6.3 Target Customers/End Users
    • 9.6.4 Analyst View
  • 9.7 Inspiralis Limited, Inc.
    • 9.7.1 Company Overview
    • 9.7.2 Product Portfolio
    • 9.7.3 Target Customers/End Users
    • 9.7.4 Analyst View
  • 9.8 Merck KGaA
    • 9.8.1 Company Overview
    • 9.8.2 Product Portfolio
    • 9.8.3 Target Customers/End Users
    • 9.8.4 Analyst View
  • 9.9 New England Biolabs (UK) Ltd.
    • 9.9.1 Company Overview
    • 9.9.2 Product Portfolio
    • 9.9.3 Target Customers/End Users
    • 9.9.4 Analyst View
  • 9.10 Promega Corporation
    • 9.10.1 Company Overview
    • 9.10.2 Product Portfolio
    • 9.10.3 Target Customers/End Users
    • 9.10.4 Analyst View
  • 9.11 QIAGEN N.V.
    • 9.11.1 Company Overview
    • 9.11.2 Product Portfolio
    • 9.11.3 Target Customers/End Users
    • 9.11.4 Analyst View
  • 9.12 SBS Genetech
    • 9.12.1 Company Overview
    • 9.12.2 Product Portfolio
    • 9.12.3 Target Customers/End Users
    • 9.12.4 Analyst View
  • 9.13 Takara Bio Inc.
    • 9.13.1 Company Overview
    • 9.13.2 Product Portfolio
    • 9.13.3 Target Customers/End Users
    • 9.13.4 Analyst View
  • 9.14 Thermo Fisher Scientific, Inc.
    • 9.14.1 Company Overview
    • 9.14.2 Product Portfolio
    • 9.14.3 Target Customers/End Users
    • 9.14.4 Analyst View
  • 9.15 Emerging Companies
    • 9.15.1 Tinzyme Ltd.
    • 9.15.2 Hotspot Therapeutics
    • 9.15.3 Nurix Therapeutics
    • 9.15.4 Vividion Therapeutics

List of Figures

  • Figure: Global Ligase Market, Dynamics Impact Analysis
  • Figure: Global Ligase Market Coverage
  • Figure: Global Ligase Market, Key Trends, Impact Analysis, 2023-2035
  • Figure: Global Ligase Market, Patent Analysis, January 2022-March 2025
  • Figure: Global Ligase Market, Competitive Landscape, January 2022-March 2025

List of Tables

  • Table: Global Ligase Market Dynamics, Impact Analysis
  • Table: Global Ligase Market (by Product Type), $Million, 2023-2035
  • Table: Global Ligase Market (by Source Type), $Million, 2023-2035
  • Table: Global Ligase Market (by Application), $Million, 2023-2035
  • Table: Global Ligase Market (by End User), $Million, 2023-2035
  • Table: Global Ligase Market (Region), $Million, 2023-2035